• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Neumora Therapeutics, Inc. - Common Stock (NQ:NMRA)

    3.020 +0.020 (+0.67%)
    Official Closing Price Updated: 4:15 PM EST, Mar 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,075,983
    Open 2.960
    Bid (Size) 2.900 (500)
    Ask (Size) 3.240 (10,000)
    Prev. Close 3.000
    Today's Range 2.935 - 3.085
    52wk Range 0.6110 - 3.650
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Fund Put $3.4 Million Into Navan Despite a 60% Post-IPO Drop ↗
    Navan delivers AI-powered travel and expense management software for enterprise clients seeking streamlined operations. 
    Via The Motley Fool
    Topics Artificial Intelligence Initial Public Offering Regulatory Compliance

    Performance

    YTD
    +81.9%
    +81.9%
    1 Month
    +49.5%
    +49.5%
    3 Month
    +36.0%
    +36.0%
    6 Month
    +79.8%
    +79.8%
    1 Year
    +98.7%
    +98.7%

    More News

    Read More
    News headline image
    Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For August 6, 2025 ↗
    Via Benzinga
    News headline image
    Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Top movers in Tuesday's pre-market session ↗
    Via Chartmill
    News headline image
    Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Neumora Therapeutics to Participate in Upcoming Conferences in November
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Unusual volume stocks in Thursday's session ↗
    Via Chartmill
    News headline image
    Unusual volume stocks in Wednesday's session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies ↗
    Via Stocktwits
    News headline image
    Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Neumora Therapeutics to Host Virtual R&D Day on October 27
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Warner Bros. Discovery Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
    Via Benzinga
    News headline image
    Neumora Therapeutics to Participate in Upcoming Conferences in September
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Neumora (NMRA) Q2 Loss Improves 10% ↗
    Via The Motley Fool
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    Boston Beer Posts Better-Than-Expected Earnings, Joins Scholastic, Deckers Outdoor, Saia And Other Big Stocks Moving Higher On Friday ↗
    Via Benzinga
    News headline image
    Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
    From Neumora Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    These stocks are moving in today's session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Neumora Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Neumora Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Neumora Therapeutics, Inc. - Common Stock trade on?
    Neumora Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Neumora Therapeutics, Inc. - Common Stock?
    The ticker symbol for Neumora Therapeutics, Inc. - Common Stock is NMRA on the Nasdaq Stock Market
    What is the current price of Neumora Therapeutics, Inc. - Common Stock?
    The current price of Neumora Therapeutics, Inc. - Common Stock is 3.020
    When was Neumora Therapeutics, Inc. - Common Stock last traded?
    The last trade of Neumora Therapeutics, Inc. - Common Stock was at 03/06/26 04:15 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.